Venture firm launches rare blood disorder therapeutics developer with $41M
Venture capital firm Third Rock Ventures has launched a drug development startup to treat genetic blood disorders, with sickle-cell anemia as its lead program target, providing $40.7 million in series A financing. Global Blood Therapeutics‘ drug development pipeline will target severe, genetic blood diseases that currently have no effective cures and limited therapeutic options. It […]